Menopause Global Prevalence and Trends: What the Data Show

How many women are postmenopausal worldwide?

A 2024 review by Women's Health Initiative investigators put the number of postmenopausal women at approximately 1.1 billion worldwide and approximately 55 million in the United States [1].

For scale within the US, FDA cited Census Bureau data showing about 41 million women aged 45 to 64 in 2020, the ages when vasomotor symptoms are most common [8]. FDA's review of US outpatient prescribing found that about 2 million women aged 46 to 65 received a prescription for systemic estrogen-alone or estrogen plus progestogen in that year, which the agency described as suggesting that menopausal hormone therapy may be under-utilized among women likely to benefit from it [8].

What is the average age at menopause?

Menopause is reached after 12 months in a row with no period; the years before it are the menopausal transition, or perimenopause, which lasts about 4 years on average and can run up to 10 [4][3]. In the US the average age is 52 [3], and the most common range is 45 to 55 [4].

Pooled data give a wider picture. A systematic review and meta-analysis of 46 studies from 24 countries found a mean age at natural menopause of 48.8 years (95% CI 48.3 to 49.2), with between-study differences partly explained by region: the mean was lowest in African, Latin American, Asian and Middle Eastern countries and highest in Europe and Australia, followed by the USA [2]. In the same analysis, current smoking was associated with menopause about 0.9 years earlier (weighted mean difference -0.91, 95% CI -1.34 to -0.48), and higher education with later menopause (high versus low education 0.64 years, 95% CI 0.26 to 1.02) [2].

Within one country the spread is narrower but still measurable. SWAN, a cross-sectional study of 14,620 women aged 40 to 55 at seven US centers across five racial and ethnic groups, reported an adjusted median age at natural menopause of 51.4 years; current smoking, lower educational attainment, being separated, widowed or divorced, not being employed, and a history of heart disease were each associated with earlier menopause, while parity, prior oral contraceptive use and Japanese race/ethnicity were associated with later menopause [9].

The standard staging system, STRAW+10, applies regardless of age, ethnicity or body size [10][11].

How common are menopausal symptoms globally?

FDA cited a 2021 study that found moderate to severe vasomotor symptoms in about 34% of women aged 45 to 65 [8].

A 2024 meta-analysis of 321 studies covering 482,067 middle-aged women estimated prevalence for 19 symptoms [12]. Joint and muscular discomfort was the most common at 65.43% (95% CI 62.51 to 68.29) and formication the least common at 20.5% (95% CI 13.44 to 28.60) [12]. Hot flash prevalence was significantly lower in high-income countries (49.72%) than in low-income (65.93%), lower-middle-income (54.17%) and upper-middle-income (54.72%) countries (p<0.01) [12]. Vaginal dryness was reported by 44.81% of postmenopausal women versus 21.16% of premenopausal women (p<0.01) [12]. Office on Women's Health says genital and urinary symptoms may get worse over time without treatment [3], and the agreed term for the combined genital, sexual and urinary symptoms is genitourinary syndrome of menopause [13].

Other pooled estimates: depression affects 35.6% of menopausal women (95% CI 32.0 to 39.2) across 55 studies and 76,817 participants, with a high degree of heterogeneity between studies [6], and sleep disorders affect 51.6% of postmenopausal women (95% CI 44.6 to 58.5) [7].

Reporting itself varies with culture. A review of studies from Japan, North America and Australia that used similar methods concluded that differences in symptom reporting between cultural groups are real, and that both biological variation and cultural differences contribute [14].

How long do symptoms last?

SWAN enrolled 3,302 women at seven US sites; analyses included 1,449 women with frequent vasomotor symptoms and found a median total duration of frequent hot flashes or night sweats of 7.4 years, with a median persistence of 4.5 years after the final menstrual period [15]. Women who were premenopausal or early perimenopausal when they first reported frequent symptoms had the longest course, a median of more than 11.8 years, and Black women reported the longest total duration of any group, a median of 10.1 years [15].

Other sources give a similar range: hot flashes and night sweats last 7 to 12 years on average [3]. Symptoms also persist into older age for a substantial minority. In a study of 3,167 older postmenopausal women with osteoporosis, 11.8% reported bothersome hot flushes at baseline, and of those with three-year data, 56.5% still had them [16].

How common are early and premature menopause?

A meta-analysis of 31 studies estimated the pooled prevalence of primary ovarian insufficiency at 3.7% (95% CI 3.1 to 4.3) and of early menopause at 12.2% (95% CI 10.5 to 14); primary ovarian insufficiency was more common in medium and low Human Development Index countries, and the prevalence did not change over the period the studies covered [5]. MedlinePlus defines menopause before age 45 as early menopause and before age 40 as premature menopause [4].

Earlier menopause carries measurable risk. A pooled analysis of individual data from 15 observational studies and 301,438 women found higher cardiovascular disease risk compared with menopause at ages 50 to 51: hazard ratio 1.55 (95% CI 1.38 to 1.73) for menopause before 40 and 1.30 (95% CI 1.22 to 1.39) for ages 40 to 44 [17].

Surgery to remove both ovaries causes menopause right away [3]. In a population-based cohort, mortality was not increased overall after bilateral oophorectomy, but mortality was higher after prophylactic bilateral oophorectomy before age 45, mainly among women who had not received estrogen through age 45 [18].

What the long-term data show

Bone. In transilial bone biopsies taken from 50 healthy women before and 12 months after their last period, median activation frequency rose from 0.13 to 0.24 per year (p<0.001); the authors report that bone remodeling rates double at menopause and triple 13 years later [19].

Heart. In the Framingham cohort of 2,873 women, an analysis of women under 55 over 20 years of observation found 20 cardiovascular events among premenopausal women and 70 among postmenopausal women of the same age [20]. A secondary analysis of the Women's Health Initiative trials found that the effect of hormone therapy on coronary heart disease varied with years since menopause: hazard ratio 0.76 (95% CI 0.50 to 1.16) within 10 years, 1.10 (0.84 to 1.45) at 10 to 19 years, and 1.28 (1.03 to 1.58) at 20 or more years (p for trend 0.02) [21].

Weight. In SWAN, DXA body-composition data showed the rate of fat gain doubling at the start of the transition and lean mass declining, both continuing until about 2 years after the final period; weight itself climbed steadily in premenopause, without acceleration at the transition, and flattened afterward [22]. A Cochrane review of 22 randomized trials found no significant weight difference between hormone therapy users and non-users (+0.66 kg with unopposed estrogen, 95% CI -0.62 to 1.93; -0.47 kg with combined therapy, 95% CI -1.63 to 0.69) [23]. A five-year Australian cohort of 233 women (106 premenopausal, 106 perimenopausal and 21 hormone therapy users at baseline) recorded a mean weight gain of 2.1 kg, with no significant difference between women who stayed premenopausal and those who became postmenopausal [24]. A narrative review reached the same conclusion: weight gain itself cannot be attributed to the transition, but total body fat and abdominal fat increase [25].

How has hormone therapy labeling changed?

FDA asked application holders on 2025-11-10 to change menopausal hormone therapy labels, and on 2026-02-12 announced approval of the first labeling changes for six products spanning four categories [26][8]. Label changes have not been universal: the current Premarin oral label still includes boxed warnings for endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia [27]. Meanwhile, the 2022 Menopause Society position statement still describes hormone therapy as the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and as shown to prevent bone loss and fracture [28].